Anti-Tumor Effects of Statins in Pancreatic Ductal Adenocarcinoma Cells

Read full text Summarise with VIRAT
Authors: Veronika Kucháriková, Zuzana Hatoková, Eva Baranovičová, Bibiána Baďurová, Tereza Pavlisova, Lucia Kotulova, Michal Kalman, Juraj Marcinek, Olga Chodelkova, Slavomíra Nováková, Ján Strnádel, Henrieta Škovierová
+1 more Erika Halášová
Cited by: 0
References: 50

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has limited effective therapeutic strategies. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and may affect tumor cell fitness via the mevalonate pathway, mitochondrial function, and redox homeostasis. We systematically compared seven statins in patient-derived PDAC cell lines and related viability effects to mitochondrial, redox, cell-cycle, apoptotic, and metabolic responses. Statins were tested in three PDAC cell lines (PDAC-1/2/3) using MTT assays (5–20 µM; 24–120 h). Based on MTT responses, mechanistic profiling was performed after 72 h at 20 µM concentration using lipophilic statins, including apoptosis (Annexin V/7-AAD), cell-cycle distribution, mitochondrial membrane potential (Δψm), intracellular ROS, and 1H-NMR quantification of intracellular and extracellular metabolites. Statins reduced viability in a concentration- and time-dependent manner, with lipophilic statins more active than hydrophilic. PDAC-1 was highly sensitive, PDAC-3 intermediate, and PDAC-2 comparatively resistant. PDAC-1 and PDAC-3 showed G0/G1 accumulation, Δψm depolarization, reactive oxygen species (ROS) elevation, and Annexin V–positive apoptosis, whereas PDAC-2 (high basal ROS) showed ROS reduction and limited apoptosis despite Δψm loss. Metabolomics indicated reduced glucose and amino-acid utilization and lactate secretion while preserving line-specific metabolic fingerprints. PDAC cell lines display marked inter-tumoral heterogeneity in statin responses, supporting evaluation of statins as chemosensitizing adjuvants in functionally guided PDAC treatment strategies.

Fields of Study & Subjects

Cancer Lipids and Metabolism Pancreatic and Hepatic Oncology Research Metabolism Diabetes and Cancer

Publication details

Journal / source
International Journal of Molecular Sciences
Volume
27
Issue
7
Pages
2972–2972
Publication date
25 March 2026
Language
EN